Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy

Схожие документы

• Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy
  по: Wardell, Suzanne E., et al.
  Опубликовано: (2019)
• The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy
  по: Wardell, Suzanne E., et al.
  Опубликовано: (2011)
• G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer
  по: Andreano, Kaitlyn J., et al.
  Опубликовано: (2020)
• Targeting mutant estrogen receptors
  по: Wardell, Suzanne E, et al.
  Опубликовано: (2019)
• Oral selective estrogen receptor downregulators (SERDs) a breakthrough endocrine therapy for breast cancer
  по: McDonnell, Donald P., et al.
  Опубликовано: (2015)